摘要: |
目的:探讨中国冠心病患者ApoE基因型和血清高敏C反应蛋白的表达及其临床意义。方法:选取2015年6月~2018年5月收入的103例冠心病患者,对其进行ApoE基因型测定。根据ApoE基因型检测结果,将研究对象划分为E2/E3,E3/E3,E3/E4+ E4/E4三组,对各组研究对象行血清高敏C反应蛋白浓度的检测,并进行统计学分析。结果:E2/E3,E3/E3,E3/E4+ E4/E4三组不同基因型患者其hs_CRP浓度为非正态分布,经轶和检验后,其轶值分别为64.85,51.40,和44.82,呈现逐步降低趋势,三者间P=0.195无显著性差异。
[结论] 在中国冠心病患者中,携带不同ApoE基因型患者其hs_CRP浓度虽无统计学差异,但仍呈现了以E2/E3,E3/E3,E3/E4+ E4/E4基因型为递减的趋势,说明携带E4基因型患者其生成CRP能力较低。在临床中,若能及时关注E4基因型患者hs_CRP浓度升高情况,可协助医务工作者判断疾病进程,更好的实现精准化治疗。 |
关键词: 冠心病 ApoE基因型 高敏C反应蛋白 |
DOI: |
分类号: |
基金项目:国家临床药学重点专科建设项目(No.30305030698) 四川省干部保健科研课题(川干研2018-212) |
|
Clinical correlation between ApoE genotype and hypersensitive C-reactive protein in Chinese patients with coronary heart disease |
|
|
Abstract: |
Objective To investigate the expression and clinical significance of ApoE genotype and hypersensitive C-reactive protein in Chinese patients with coronary heart disease.Methods ApoE genotype was determined in 103 patients with coronary heart disease from June 2015 to May 2018. According to the ApoE genotype, the subjects were divided into E2/E3, E3/E3 and E3/E4+E4/E4 groups. The serum levels of hypersensitivity C-reactive protein (hs_CRP) were detected and analyzed statistically. Results The concentrations of hs_CRP in E2/E3, E3/E3, E3/E4+E4/E4 genotypes were non-normal distribution, and the anecdotal values were 64.85, 51.40, and 44.82, respectively, showing a gradual decreasing trend. There was no significant difference among the three genotypes (P = 0.195). Conclusion Although there was no significant difference in the concentration of hs_CRP among the patients with different ApoE genotypes in CHD, the genotypes of E2/E3, E3/E3, E3/E4+E4/E4 still showed a decreasing trend, indicating that the patients with E4 genotype had a lower CRP production capacity. In clinical practice, if we can pay close attention to the increase of hs_CRP concentration in E4 genotype patients in time, it can help us to judge the course of disease and achieve better precision treatment. |
Key words: coronary heart disease ApoE genotype hypersensitive C-reactive protein |